<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552197</url>
  </required_header>
  <id_info>
    <org_study_id>CR108808</org_study_id>
    <secondary_id>2020-000167-24</secondary_id>
    <secondary_id>64251330EDI1003</secondary_id>
    <nct_id>NCT04552197</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-64251330 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-Label, Multi-Dose Study to Assess the Systemic and Local Tissue Pharmacokinetics and Pharmacodynamics of JNJ-64251330 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate: systemic and local gut (rectum and sigmoid colon)&#xD;
      exposure to JNJ-64251330, local tissue Pharmacodynamics (PD) using gut (rectum and sigmoid&#xD;
      colon) biopsies (Part 1) and the effect of food on the rate and extent of absorption of&#xD;
      JNJ-64251330 from oral tablet dosed with or without food (Part 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Actual">December 29, 2020</completion_date>
  <primary_completion_date type="Actual">December 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Maximum Observed Plasma Concentrations (Cmax) of JNJ-64251330</measure>
    <time_frame>Predose, 0.25 hour (h), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h Postdose on Day 1 and Day 5; Predose on Day 2</time_frame>
    <description>Cmax is maximum observed plasma concentrations during a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Trough Observed Plasma Concentration (Ctrough) of JNJ-64251330</measure>
    <time_frame>Predose, 24 hour (h) Postdose on Day 5</time_frame>
    <description>Ctrough is observed plasma concentration immediately prior to dosing on Day 5 and 24 h after last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-Time Curve from 0 to 24 Hour (AUC [0-24 h]) of JNJ-64251330</measure>
    <time_frame>Predose, 0.25 hour (h), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 14 h, 24 h Postdose on Day 1 and Day 5; Predose on Day 2</time_frame>
    <description>AUC (0-24 h) is defined as area under the plasma concentration-time curve from time 0 to 24 hours postdose will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUC [0-Last]) of JNJ-64251330</measure>
    <time_frame>Predose, 0.25 hour (h), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 14 h, 24 h Postdose on Day 1 and Day 5; Predose on Day 2</time_frame>
    <description>AUC (0-Last) is defined as area under the plasma concentration versus time curve from time 0 to time of the last quantifiable concentration will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Biopsy Gut (Rectum and Sigmoid Colon) Tissue Concentration of JNJ-64251330</measure>
    <time_frame>Day 6</time_frame>
    <description>Biopsy gut (rectum and sigmoid colon) tissue concentration of JNJ-64251330 will be measured using liquid chromatography-mass spectrometry/mass spectrometry (LC MS/MS) assay method to evaluate systemic and local gut (rectum and sigmoid colon) exposure to JNJ-64251330.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in Levels of Phosphorylated Signal Transducer and Activator of Transcription (pSTATs) and other Pan-Janus kinase (JAK) Biomarkers</measure>
    <time_frame>Baseline up to Day 6</time_frame>
    <description>Change from baseline in levels of pSTATs and other JAK biomarkers in gut (rectum and sigmoid colon) biopsies as a function of compound and dose will be measured to evaluate local tissue pharmacodynamics (PD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Maximum Observed Plasma Concentrations (Cmax) of JNJ-64251330</measure>
    <time_frame>Predose, 0.25 hour (h), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h Postdose on Day 1; 24 h, 32 h, 36 h Postdose on Day 2; 48 h Postdose on Day 3</time_frame>
    <description>Cmax is maximum observed plasma concentrations during a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Time to achieve Maximum Observed Plasma Concentration (Tmax) of JNJ-64251330</measure>
    <time_frame>Predose, 0.25 hour (h), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h Postdose on Day 1; 24 h, 32 h, 36 h Postdose on Day 2; 48 h Postdose on Day 3</time_frame>
    <description>Tmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Plasma Concentration-Time Curve from Time 0 to 24 Hour (AUC [0-24 h]) of JNJ-64251330</measure>
    <time_frame>Predose, 0.25 hour (h), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h Postdose on Day 2</time_frame>
    <description>AUC (0-24 h) defined as area under the plasma concentration-time curve from time 0 to 24 hour postdose will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUC [0-Last]) of JNJ-64251330</measure>
    <time_frame>Predose, 0.25 hour (h), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h Postdose on Day 1; 24 h, 32 h, 36 h Postdose on Day 2; 48 h Postdose on Day 3</time_frame>
    <description>AUC (0-Last) defined as area under the plasma concentration versus time curve from time 0 to time of the last quantifiable concentration will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Plasma Concentration-Time Curve from Time 0 to Infinite Time (AUC [0-Infinite]) of JNJ-64251330</measure>
    <time_frame>Predose, 0.25 hour (h), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h Postdose on Day 1; 24 h, 32 h, 36 h Postdose on Day 2; 48 h Postdose on Day 3</time_frame>
    <description>AUC (0-Infinite) defined as area under the analyte concentration versus time curve from time 0 to infinite time will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 35 days (Part 1); Up to 39 days (Part 2)</time_frame>
    <description>Incidence of AEs will be evaluated to assess the safety and tolerability of JNJ 64251330 and tofacitinib. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Severity of AEs</measure>
    <time_frame>Up to 35 days (Part 1); Up to 39 days (Part 2)</time_frame>
    <description>Severity assessment for an AE will be completed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 5.0). Severity grades ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening or Disabling and Grade 5= Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Ratio of Gut (Rectum and Sigmoid colon) to Systemic Exposure</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>Ratio of gut (rectum and sigmoid colon) to systemic exposure will be evaluated to assess the relative exposure of JNJ-64251330 versus tofacitinib.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Treatment A (JNJ-64251330)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-64251330 (dose 1), once daily for 5 days under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Treatment B (JNJ-64251330)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-64251330 (dose 1), twice daily for 5 days under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Treatment C (JNJ-64251330)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-64251330 (dose 2), twice daily for 5 days under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Treatment D (JNJ-64251330)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive tofacitinib tablet twice daily for 5 days under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Treatment EF (JNJ-64251330)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Treatment FE (JNJ-64251330)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64251330</intervention_name>
    <description>JNJ-64251330 tablet will be administered orally.</description>
    <arm_group_label>Part 1: Treatment A (JNJ-64251330)</arm_group_label>
    <arm_group_label>Part 1: Treatment B (JNJ-64251330)</arm_group_label>
    <arm_group_label>Part 1: Treatment C (JNJ-64251330)</arm_group_label>
    <arm_group_label>Part 2: Treatment EF (JNJ-64251330)</arm_group_label>
    <arm_group_label>Part 2: Treatment FE (JNJ-64251330)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>Tofacitinib tablets will be administered orally.</description>
    <arm_group_label>Part 1: Treatment D (JNJ-64251330)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI; weight [kilogram {kg}]/height^2 [meter {m}]^2) between 18.0 and&#xD;
             30.0 kilograms per meter square (kg/m^2) (inclusive), and body weight not less than&#xD;
             50.0 kg&#xD;
&#xD;
          -  12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and&#xD;
             function, including: QTc interval less than or equal to (&lt;=) 450 milliseconds (ms) for&#xD;
             men and &lt;= 470 ms for women&#xD;
&#xD;
          -  Healthy on the basis of clinical laboratory tests performed at screening. If the&#xD;
             results of the serum chemistry panel, lipid panel, hematology, coagulation or&#xD;
             urinalysis are outside the normal reference ranges, the participant may be included&#xD;
             only if the investigator judges the abnormalities or deviations from normal to be not&#xD;
             clinically significant. This determination must be recorded in the participant's&#xD;
             source documents and initialed by the investigator&#xD;
&#xD;
          -  Have participant-reported normal consistency, regular bowel movements&#xD;
&#xD;
          -  A woman must have a negative highly sensitive serum (beta-human chorionic gonadotropin&#xD;
             [hCG])&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hepatic or renal insufficiency; significant cardiac, vascular, pulmonary,&#xD;
             endocrine, hematologic, rheumatologic, neurologic, oncologic, or psychiatric disease,&#xD;
             or metabolic disturbances or any other illness that the investigator considers should&#xD;
             exclude the participant or that could interfere with the interpretation of the study&#xD;
             results&#xD;
&#xD;
          -  Active or chronic infection, a nontuberculous mycobacterial infection, or&#xD;
             opportunistic infection (example, pneumocystosis and aspergillosis)&#xD;
&#xD;
          -  History of severe allergic reaction to midazolam&#xD;
&#xD;
          -  Contraindications to the use of tofacitinib per summary of product characteristics&#xD;
             (SmPC)^14/ local prescribing information&#xD;
&#xD;
          -  Female participant who is a breastfeeding mother&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

